2,628 reports of this reaction
1.7% of all RIBAVIRIN reports
#17 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #17 most commonly reported adverse reaction for RIBAVIRIN, manufactured by Bausch Health US, LLC. There are 2,628 FDA adverse event reports linking RIBAVIRIN to HAEMOGLOBIN DECREASED. This represents approximately 1.7% of all 157,291 adverse event reports for this drug.
RIBAVIRIN has an overall safety score of 85 out of 100. Patients taking RIBAVIRIN who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is a less commonly reported adverse event for RIBAVIRIN, but still significant enough to appear in the safety profile.
In addition to haemoglobin decreased, the following adverse reactions have been reported for RIBAVIRIN:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 2,628 FDA reports for RIBAVIRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 1.7% of all adverse event reports for RIBAVIRIN, making it a notable side effect.
If you experience haemoglobin decreased while taking RIBAVIRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.